Kayexalate Emerging Litigation

Emerging Kayexalate Litigation

Kayexalate: An emerging litigation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Kayexalate, made by Concordia Pharmaceuticals, Inc. was first approved by the FDA subsequent to New Drug Application 011287.

September 2017 : FDA is recommending that patients avoid taking the potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) at the same time as other medicines taken by mouth. A study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medicines, decreasing the absorption and therefore effectiveness of those oral medicines.

A study was conducted in the laboratory, called an in vitro study, to evaluate the binding potential for certain administered medicines commonly taken together with sodium polystyrene sulfonate. These medicines included certain:

Blood pressure medicines

Antibiotics

Seizure Medications

Blood Thinner Medication

Furosemide

By reducing or eliminating the effectiveness of other drugs, patients may be more likely to suffer adverse events intended to be controlled by the effected drugs.

Prior to the September 2017 FDA action, the Kayexalate label included warnings related to the concomitant use of several drugs however, these warnings did not include a significant number of drugs now found to be potentially harmful when used in combination with Kayexalate.

To Learn More About the Emerging Kayexalate Litigation:

The emerging Kayexalate Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Kayexalate Litigaton, using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Michael Brady Lynch>

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 


Share this Post: